Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

iDoseTR Approval Sets Stage for Glaukos’ Game-Changing Product, Surpassing Market Expectations, Says Analyst

By Vandana Singh
December 15, 2:49 PM
Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension 

GKOS

Read More
1 minute read

Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst

By Vandana Singh
July 19, 2:26 PM
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside is expected from the accelerating iAccess and iPRIME launches.

GKOS